Select Page
en
arzh-CNnlenfrdeitptrues

Research

The Bow Foundation funds cutting edge research to benefit those with GNAO1 – related neurodevelopmental disorders and other similar rare diseases and neurological conditions. We’re currently accepting grant applications for future GNAO1 research studies.

Supported Research

University of Virginia Research Project

In August of 2017, the Bow Foundation funded a $100,000 research grant to the University of Virginia to support a GNAO1 – related neurodevelopmental disorder study led by Dr. Michael McConnell.  Using a tiny skin sample from two GNAO1 patients, Dr. McConnell created induced pluripotent stem cells (iPSCs) to better understand subtle differences between GNAO1 patients and better understand how GNAO1 disorders respond to certain drug treatments. The research has the potential to increase understanding of GNAO1 genetic disorders and may ultimately lead to new or better treatments.

To read more about the grant, click here. The second grant of $50,000 was made in the winter of 2018.

Michigan State University Research Project

In June of 2018, the Bow Foundation funded a $48,000 research project at Michigan State University to support a study of mouse models with GNAO1-related neurodevelopmental gene mutations. Through the study, researchers will gather more information about GNAO1, test existing drugs, and identify possible new treatment options.  The research project will be led by Dr. Richard Neubig, Chair of Michigan State’s Department of Pharmacology & Toxicology.

Click here to read more about the grant announcement.

Washington University Natural History Study

In March of 2019, the Bow Foundation funded a $65,000 research project at Washington University to help with the costs of the three-day research clinic at St. Louis Children’s Hospital to begin a Natural History study of GNAO1.

Click here to read more about the 2019 clinic.

Stanford Research Project

GNAO1 families have been invited to participate in a research study of adaptive behaviors in children with early life epilepsy. The study is open to all GNAO1 patients, even those who do not have epilepsy. Stanford Children’s Health is working to develop a metric that may serve as a way to track response to treatment in future clinical studies.

You will be asked questions about your child’s seizures, and/or movement disorder and medications. You will be asked to complete an online survey through a secure data collection website. Then you will be asked to complete an online questionnaire about your child’s behaviors in social, motor, daily living and communication domains.

Dr. Jojo Yang from Stanford Children’s Health, is leading this project. You can fill out the questionnaire by clicking the link below or by contacting Dr. Yang (jojoyang@stanford.edu)

https://is.gd/stanfordepilepsybehaviorstudy